Julio Sokolich, MD
Transplant Surgery · van Nuys, CANPI 1003010794
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,502 of the $2,281 with a category attached, or 65.9%. 23 manufacturers reported payments, led by Organox Ltd at 34.1% of the total. 2025 is the largest year on record at $807, 2.4 times the $336 reported in 2019. That places this record below the midpoint for transplant surgery clinicians in CA, where the typical reported total is $2,317.
Across 38 payments — averaging $60.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organox Ltd$779
- Intuitive Surgical$499
- Eisai Inc.$116
- Exelixis Inc.$111
- Karyopharm Therapeutics Inc.$110
- Veloxis Pharmaceuticals, Inc.$108
- plus $558 from 17 others
What the payments were for
- Travel & lodging$77934%
- Food & beverage$1,50266%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organox Ltd | 1 | $779 |
| Intuitive Surgical | 5 | $499 |
| Eisai Inc. | 1 | $116 |
| Exelixis Inc. | 1 | $111 |
| Karyopharm Therapeutics Inc. | 4 | $110 |
| Veloxis Pharmaceuticals, Inc. | 1 | $108 |
| Johnson & Johnson | 3 | $82 |
| Amgen | 4 | $79 |
| Bayer | 3 | $47 |
| Ipsen Biopharmaceuticals, Inc | 2 | $45 |
| Blue Earth Diagnostics | 1 | $29 |
| Novartis | 1 | $28 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Boston Scientific | 1 | $27 |
| Puma Biotechnology, Inc. | 1 | $26 |
| Blueprint Medicines Corporation | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Incyte Corporation | 1 | $24 |
| Seagen Inc. | 1 | $23 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| G1 Therapeutics, Inc. | 1 | $19 |
| Epizyme, Inc. | 1 | $18 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- METRA$779
- Da Vinci Surgical System$465
- Envarsus$216
- LENVIMA$116
- Cabometyx$111
How this compares
$2,281 in reported general payments places this provider in the 45th percentile of 56 transplant surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in van Nuys
- Elizabeth SquiersHalf Moon Bay$1.3M
- Myron TongPasadena$99K
- Robert RedfieldOrange$65K
- Yuri GenykLos Angeles$35K
- Angeles Baquerizola Jolla$28K
- Navpreet KaurLos Angeles$19K
- Gerald LipshutzLos Angeles$16K
- Maria StapferFullerton$15K
- Steven WiselWest Hollywood$13K
- Mohd SheikhLos Angeles$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.